Divi's Laboratories vs Sunpharma Q3 FY26

Divis Laboratories reported Q3 FY26 consolidated total income of INR 2,692 crore, up 12% YoY, driven by strong custom synthesis (57% mix) and stable generics volume. PAT stood at INR 583 crore, flat YoY due to a one-time exceptional item of INR 74 crore from labour code changes. Gross margins improved sharply to 63.7% (material consumption 36.3% of sales vs 39.8% last year) on favourable product mix. Management highlighted three dedicated CS projects progressing towards commercialization by Q3-Q4 CY2027, with validations ongoing. Peptide capabilities advanced with a dedicated commercial building for SPPS. Nutraceuticals contributed INR 214 crore in the quarter. Risks include continued generic pricing pressure and potential input cost impact from China's export tax rebate withdrawal. Overall, the company is well-positioned for double-digit growth with a strong pipeline and capacity expansion.

Guidance read

Three dedicated CS projects to commercialize by Q3-Q4 CY2027: Three custom synthesis molecules currently in validation/regulatory approval stages are expected to start commercial volumes in the second half of calendar year 2027. Double-digit revenue growth trajectory maintained: Management reiterated expectation of double-digit constant currency growth, supported by a balanced pipeline across patent phases. Phase two expansion at Kakinada under evaluation: Company is evaluating a second phase expansion at Unit 3 with 4 additional production blocks, but no final decision or timeline announced.

Risk read

Key risks include Generic pricing pressure persists — Pricing environment for generics remains competitive, limiting value growth despite volume increases.; China export tax rebate withdrawal may increase input costs — China's removal of export tax rebates on certain chemicals could lead to selective pricing pressures on raw materials, though company has diversified 78% of procurement domestically.; Regulatory approval delays for CS projects — Commercialization of three dedicated CS projects depends on customer regulatory approvals, which could face delays beyond the guided Q3-Q4 CY2027 timeline.; Concentration risk in peptide segment — Peptide capacity is largely dedicated to a single customer's requirements, creating dependency; management declined to disclose details on diversification..

Promise ledger

Of 2 tracked promises, management 0 met, 0 close, 2 missed.

Sun Pharma delivered a strong Q3 FY26 with consolidated revenue of INR 15,469 crore (+15.1% YoY) and EBITDA of INR 4,949 crore (+23.4% YoY), driven by broad-based growth in India (+16.2%) and emerging markets (+21.6%), partially offset by flat US sales. EBITDA margin expanded to 31.9% on better product mix, while PAT grew 16% to INR 3,369 crore despite a higher tax rate. Management highlighted the upcoming launch of generic semaglutide in India as a key growth catalyst, with approvals received for both diabetes and weight management. However, US generic sales remain under pressure from competition and manufacturing compliance issues, and the company faces uncertainty from proposed US pricing reforms. The strong balance sheet (net cash $3.2B) provides M&A flexibility, though management remains disciplined.

Guidance read

Semaglutide launch in India on patent expiry: Sun Pharma plans to launch generic semaglutide in India on day one of patent expiry for both chronic weight management and type 2 diabetes, under brands NovelTreat and SemaTrinity. R&D spend guidance for next year: Management indicated they will provide R&D spend guidance for the next fiscal year in the next quarter's call. Phase 2b trial for GL0034 to complete in 12-18 months: The phase 2b study for GL0034 in type 2 diabetes has started and is expected to complete within 12-18 months.

Risk read

Key risks include US generic sales pressure from competition — US generic sales declined due to additional competition on certain products, and recovery depends on resolving manufacturing compliance issues at several sites.; Proposed US Most Favored Nation pricing models — CMS proposed pricing models could impact US revenues; management declined to share mitigation strategies, citing commercial sensitivity.; Higher effective tax rate impacting PAT growth — Effective tax rate rose to ~25% from ~15% last year, dampening PAT growth relative to EBITDA growth; expected to remain in that range.; Milestone income may not recur — Management noted that milestone income of $55 million in Q3 may not recur in future quarters, potentially impacting revenue comparability..

Promise ledger

Of 3 tracked promises, management 0 met, 0 close, 3 missed.